{"name":"Usynova Pharmaceuticals Ltd.","slug":"usynova-pharmaceuticals-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNcDRUdktlWHljR3FtVlNOT3JHS2gtMzNMaXNuQzBBX3ctNjdyd21hNzE3TFhrb2xFVkVLd3lzRXhhYUlCNk1CVkRhQ2twdWdnRkNJYXRxa1ZwOWNqMGZ0UUp0WjZpTkoyNzRWeVZWTnZRSk05S3dhdmZwTmVRQ2tFNFpKNTRZMjVDd2xIVHdOWks2Sl9hU2l3NjZhTXNYSzBxREhwMEtUOA?oc=5","date":"2025-12-22","type":"pipeline","source":"Fierce Biotech","summary":"AstraZeneca fronts $100M for Jacobio's clinical-stage pan-KRAS inhibitor - Fierce Biotech","headline":"AstraZeneca fronts $100M for Jacobio's clinical-stage pan-KRAS inhibitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNN0N4SS1KSGJZdXo2dnhoMEx6QnFQTTRXZVpyQVFRa21Ic2F0X3dvTmxzOHljajF4ZmE4R0Fza3hwa0hOZGVmS19uLThDNDc3UThfUTJFLWRpdXNWaXB0RlprR29KV3VHV3N5VEwwWjE0ZEZ1NE1CT3Ria1A3c3hOVDN1TlZSeFE2Mm1OaXhaVDdkSTRoZW82M0Y2dGYtSTM0aEVYQTUtNDRNUWVuandWakpwTFBXV0E5?oc=5","date":"2023-11-24","type":"deal","source":"PMLiVE","summary":"AstraZeneca gains rights to Usynova’s KRAS inhibitor in deal worth almost $420m - PMLiVE","headline":"AstraZeneca gains rights to Usynova’s KRAS inhibitor in deal worth almost $420m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQdW9VTjhPRWZQeVoxTmw5UTgza185MzRjLUJPWi0zQzlfRFFwVGNfWGxIeWduMjdOMXFJSU9EcldBRC1DTFR1eVZkM2ltVkZ2RTVYX0FVOEszZjEtNjh3cW1aTXdaY1VvYlRyZzAyVWE4THNRUnhyMzVLb3J3UlZnWDdiRQ?oc=5","date":"2023-11-23","type":"deal","source":"pharmaphorum","summary":"AstraZeneca joins KRAS push in cancer with Chinese deal - pharmaphorum","headline":"AstraZeneca joins KRAS push in cancer with Chinese deal","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}